Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101

被引：12
|
作者：
Riyahi, Niknam [1 ]
Safaroghli-Azar, Ava [1 ]
Sheikh-Zeineddini, Negar [1 ]
Sayyadi, Mohamad [1 ]
Bashash, Davood [2 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Dept Hematol & Blood Banking, Sch Allied Med Sci, Student Res Comm, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Dept Hematol & Blood Banking, Sch Allied Med Sci, Tehran, Iran
来源：
CANCER INVESTIGATION | 2019年 / 37卷 / 07期
关键词：
Acute leukemia; c-Myc; PI3K pathway; CAL-101; 10058-F4; CELLS; APOPTOSIS; 10058-F4; PROLIFERATION; PROGRESSION; TELOMERASE; TRANSITION; MECHANISM; AUTOPHAGY; PATHWAYS;
D O I：
10.1080/07357907.2019.1651328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Enthusiasms into the application of PI3K-delta inhibitor CAL-101 has been muted due to the over-activation of compensatory molecules. Our results delineated that c-Myc suppression using 10058-F4 enhanced CAL-101 cytotoxicity in less sensitive cells through different mechanisms based on p53 status; while CAL-101-plus-10058-F4 induced G1 arrest in wild-type p53-expressing leukemic cells, no conspicuous increase in G1 was noted in U937 cells harboring mutant p53. Conclusively, this study shed lights on the role of c-Myc oncoprotein in acute leukemia cells sensitivity to PI3K inhibitor and outlined that the combination of c-Myc inhibitor and CAL-101 may be a promising therapeutic approach in leukemia.
引用
收藏
页码：311 / 324
页数：14
相关论文
共 50 条
  • [31] Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
    Gremke, Niklas
    Besong, Isabelle
    Stroh, Alina
    von Wichert, Luise
    Witt, Marie
    Elmshaeuser, Sabrina
    Wanzel, Michael
    Fromm, Martin F.
    Taudte, R. Verena
    Schmatloch, Sabine
    Karn, Thomas
    Reinisch, Mattea
    Hirmas, Nader
    Loibl, Sibylle
    Wuendisch, Thomas
    Litmeyer, Anne-Sophie
    Jank, Paul
    Denkert, Carsten
    Griewing, Sebastian
    Wagner, Uwe
    Stiewe, Thorsten
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [32] CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    Lannutti, Brian J.
    Meadows, Sarah A.
    Herman, Sarah E. M.
    Kashishian, Adam
    Steiner, Bart
    Johnson, Amy J.
    Byrd, John C.
    Tyner, Jeffrey W.
    Loriaux, Marc M.
    Deininger, Mike
    Druker, Brian J.
    Puri, Kamal D.
    Ulrich, Roger G.
    Giese, Neill A.
    BLOOD, 2011, 117 (02) : 591 - 594
  • [33] Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling
    Fulda, Simone
    MITOCHONDRION, 2014, 19 : 85 - 87
  • [34] Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC
    Liao, Jipei
    Yang, Zejia
    Abarzarzin, Shirin
    Cullen, Kevin J.
    Dan, Hancai
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (05): : 1126 - 1135
  • [35] A natural inhibitor of c-Met that sensitizes head and neck cancer cells resistant to EGFR and PI3K co-targeting
    Anisuzzaman, Asm
    Hague, Abedul
    Butler, Brian
    Amin, Arm R.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia
    Swords, Ronan T.
    Schenk, Tino
    Stengel, Sven
    Sylvina, Veronica
    Petrie, Kevin R.
    Perez, Aymee
    Ana, Rodriguez
    Watts, Justin M.
    Vargas, Fernando
    Elias, Roy
    Zelent, Arthur
    BLOOD, 2015, 126 (23)
  • [37] A phase I/II study of the selective phosphatidylinositol 3-kinase -delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)
    Furman, Richard R.
    Barrientos, Jacqueline Claudia
    Sharman, Jeff Porter
    De Vos, Sven
    Leonard, John
    Coutre, Steven E.
    Schreeder, Marshall T.
    Wagner-Johnston, Nina D.
    Boyd, Thomas E.
    Fowler, Nathan Hale
    Flinn, Ian W.
    Boccia, Ralph V.
    Holes, Leanne
    Lannutti, Brian Joseph
    Johnson, Dave
    Jahn, Thomas Michael
    Miller, Langdon L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] DEMONSTRATION OF PHARMACODYNAMIC TARGET INHIBITION AND CHEMOKINE MODULATION IN PATIENTS WITH CLL FOLLOWING TREATMENT WITH CAL-101, A SELECTIVE INHIBITOR OF THE P110 DELTA ISOFORM OF PI3K
    Lannutti, J.
    Meadows, A.
    Kashishian, A.
    Steiner, B.
    Webb, K.
    Peterman, S.
    Yu, A.
    Giese, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 45 - 46
  • [39] CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies
    Lannutti, Brian J.
    Meadows, Sarah A.
    Kashishian, Adam
    Steiner, Bart
    May, Sarah
    Johnson, Amy J.
    Ulrich, Roger G.
    Yu, Albert
    Gallatin, Michael W.
    Byrd, John C.
    Puri, Kamal D.
    Giese, Neill A.
    BLOOD, 2008, 112 (11) : 12 - 12
  • [40] Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
    Martelli, Alberto M.
    Evangelisti, Camilla
    Chiarini, Francesca
    Grimaldi, Cecilia
    Manzoli, Lucia
    McCubrey, James A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1333 - 1349
12345